噻托溴铵奥达特罗能倍乐用多长时间有效果

Chronic obstructive pulmonary disease (COPD) is mainly characterized by shortness of breath (difficulty breathing), coughing, wheezing, and sputum (mucus or purulent). In my country, the number of deaths due to COPD is as high as 1.28 million every year, seriously threatening people's lives and health. In June 2014, German pharmaceutical giant Boehringer Ingelheim (BI) announced that its new soft mist inhalation device, Sliva (tiotropium bromide/olodaterol), was officially launched in China.

The TIOSPIRTM trial verified that Spirax Respimat (tiotropium bromide, olodaterol Respimat) 2.5 μg (once a day, 2 puffs) and Spirava Respimat (HandiHaler) 18 μg have similar safety and effectiveness. Both dosage forms of Spirava Respimat are in a leading position in the maintenance treatment of COPD.

Professor Antonio Anzueto, a professor of respiratory/emergency medicine at the University of Texas Health Science Center and a trial investigator, said: TIOSPIR is a landmark clinical trial that provides a large sample database and verifies the safety and effectiveness of tiotropium bromide, whether it is used with Sutra or Respimat. More importantly, this large sample and rigorously designed clinical trial evidence shows that tiotropium bromide is safe for the majority of COPD patients, including those with a history of heart disease.

Tiotropium bromide and olodaterol have undoubtedly effectively alleviated patients' respiratory problems and brought new options for the treatment of COPD patients at home and abroad. Tiotropium bromide, olodaterol and Respimat cannot be used as rescue drugs. Patients only need to use them once a day. It is best to take the medicine at the same time every day and do not exceed the recommended dose.

Recommended related hot articles: /newsDetail/83762.html